Walvax Biotechnology Co

Walvax Biotechnology Co EBITDA per Employee

The EBITDA per Employee of Walvax Biotechnology Co (300142.SZ) as of Oct 24, 2026 is 110,125.10 CNY. In the previous year, EBITDA per Employee was 133,152.07 CNY — a change of -17.29% (lower).

EBITDA per Employee

110,125.10CNY

YoY

-17.29%

Last updated:

EBITDA per Employee of Walvax Biotechnology Co is 2025 110,125.10 CNY. EBITDA per Employee of Walvax Biotechnology Co was 2024 133,152.07 CNY. It decreases by -17.29% lower compared to the previous year.

The Walvax Biotechnology Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
99,909.10 CNY
Jan 1, 2019
148,758.70 CNY
Jan 1, 2020
752,080.12 CNY
Jan 1, 2021
404,474.81 CNY
Jan 1, 2022
620,742.93 CNY
Jan 1, 2023
375,228.51 CNY
Jan 1, 2024
133,152.07 CNY
Jan 1, 2025
110,125.10 CNY
The Walvax Biotechnology Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
110,125.10CNY-17.29%
133,152.07CNY-64.51%
375,228.51CNY-39.55%
620,742.93CNY+53.47%
404,474.81CNY-46.22%
752,080.12CNY+405.57%
148,758.70CNY+48.89%
99,909.10CNY-414.86%
-31,731.37CNY-128.80%
110,179.35CNY-123.95%
-460,002.44CNY-505.35%
113,484.15CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Walvax Biotechnology Co Stock analysis

What does Walvax Biotechnology Co do? Walvax Biotechnology Co Ltd is a leading Chinese biotech company specializing in the research, development, production, and marketing of vaccines, antibodies, and diagnostic reagents. The company was founded in 2001 and is headquartered in Beijing. Over the past 20 years, the company has become one of the largest and most advanced biotech companies in the country, capable of offering high-quality and cost-effective products. Walvax Biotechnology is committed to promoting public health and improving people's quality of life. The business model of Walvax Biotechnology is based on the integration of research and development, production, and distribution. The company offers a wide range of products and services and works closely with government agencies and other partners to improve healthcare in China and abroad. The company has various segments, including research and development, vaccine and biological drug production, diagnostic reagent production, and the distribution of medical devices and products. The research and development sector of Walvax Biotechnology has enabled the company to develop a variety of vaccines and biological drugs that contribute to the prevention and treatment of diseases. Some of the company's key vaccines include the Hepatitis A vaccine, Hepatitis E vaccine, rabies vaccine, varicella vaccine, and polio vaccine. In addition, the company has also developed antibody products that can be used for the treatment of cancer and other diseases. Some of the company's key products include the humanized monoclonal antibody against Epidermal Growth Factor Receptor (EGFR) and the humanized monoclonal antibody against Programmed Death-1 (PD-1) receptor. Walvax Biotechnology is also a major producer of diagnostic reagents used for the identification of infections and other diseases. Some of the company's key products include the HIV-ELISA test, HCV-ELISA test, and HBsAg-ELISA test. The distribution sector of Walvax Biotechnology includes the sale of medical devices and products such as blood collection needles and infusion sets. The company has also established partnerships with other companies and organizations to promote the sales and distribution of its products on an international level. Overall, Walvax Biotechnology Co Ltd has become one of China's leading biotech companies. The company has a strong presence in the vaccine industry and has gained a reputation as an innovator and producer of high-quality products. The company is committed to continuing to grow and expand its range of products and services to make a positive contribution to public health. Walvax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Walvax Biotechnology Co stock

EBITDA per Employee of Walvax Biotechnology Co is 110,125.10 CNY in 2025.

EBITDA per Employee of Walvax Biotechnology Co changed from 133,152.07 CNY to 110,125.10 CNY, representing a -17.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Walvax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Walvax Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Walvax Biotechnology Co

All Key Metrics — Walvax Biotechnology Co